Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand?

被引:14
作者
Mano, Max S. [1 ]
Rosa, Daniela D. [1 ]
Dal Lago, Lissandra [1 ]
机构
[1] Inst Jules Bordet, Unite Oncol Med, B-1000 Brussels, Belgium
关键词
international research; drug costs; developing countries; health economies;
D O I
10.1016/j.ejca.2006.02.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
International collaboration has undoubtedly played a key role in the extraordinary progress we have witnessed in some areas of oncology in recent years. It has allowed us, for instance, to design trials large enough to depict very small benefits, as well as high-quality trials in less incident types of cancer. For different reasons, developing countries have also shown growing interest in this international effort and have been participating in many international trials. However, the ever-growing costs of novel anti-cancer treatments and technologies have created unprecedented difficulties for health economies in developing countries. Although the issue of individual benefit for patients must also be taken into account, the actual benefit for their society may be minimal. This paper discusses the ethics of including patients from non-developed countries in clinical trials evaluating the role of treatments that are unlikely to be made available to them after the trial because of prohibitive costs. Upfront arrangements ensuring post-trial access to interventions that have been proven successful might be the best alternative to exclusion from the research. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2675 / 2677
页数:3
相关论文
共 11 条
  • [1] Treatment guidelines for adjuvant breast cancer are moving toward double standards: One for the rich and one for the poor
    Demonty, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9436 - 9437
  • [2] Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer
    du Bois, A
    Rochon, J
    Lamparter, C
    PFisterer, J
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (02) : 183 - 191
  • [3] The benefit of participating to clinical research
    Hébert-Croteau, N
    Brisson, J
    Lemaire, J
    Latreille, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 91 (03) : 279 - 281
  • [4] The burden of scientific progress: Growing inequalities in the delivery of cancer care
    Mano, M
    [J]. ACTA ONCOLOGICA, 2006, 45 (01) : 84 - 86
  • [5] Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
    Marty, M
    Cognetti, F
    Maraninchi, D
    Snyder, R
    Mauriac, L
    Tubiana-Hulin, M
    Chan, S
    Grimes, D
    Antón, A
    Lluch, A
    Kennedy, J
    O'Byrne, K
    Conte, P
    Green, M
    Ward, C
    Mayne, K
    Extra, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) : 4265 - 4274
  • [6] National Bioethics Advisory Commission (NBAC), 2001, ETH POL ISS INT RES
  • [7] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1659 - 1672
  • [8] Anticancer drug discovery and development throughout the world
    Schwartsmann, G
    Ratain, MJ
    Cragg, GM
    Wong, JE
    Saijo, N
    Parkinson, DR
    Fujiwara, Y
    Pazdur, R
    Newman, DJ
    Dagher, R
    Di Leone, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 47S - 59S
  • [9] SLAMON D, 2005, SAN ANT BREAST CANC
  • [10] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    Slamon, DJ
    Leyland-Jones, B
    Shak, S
    Fuchs, H
    Paton, V
    Bajamonde, A
    Fleming, T
    Eiermann, W
    Wolter, J
    Pegram, M
    Baselga, J
    Norton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 783 - 792